The current treatment for Peyronie 0 s disease (PD) is limited to surgery or collagenase injections highlighting the importance of finding novel medical therapeutic approaches particularly for early phase PD patients. The aim of this study was to test a PDE5 inhibitor and an oestrogen receptor modulator and their combination in an animal model of PD. The two targets were previously identified by a phenotypic screening assay measuring myofibroblast transformation.
INTRODUCTION AND OBJECTIVES:
The current treatment for Peyronie 0 s disease (PD) is limited to surgery or collagenase injections highlighting the importance of finding novel medical therapeutic approaches particularly for early phase PD patients. The aim of this study was to test a PDE5 inhibitor and an oestrogen receptor modulator and their combination in an animal model of PD. The two targets were previously identified by a phenotypic screening assay measuring myofibroblast transformation.
METHODS: 40 male Sprague-Dawley rats (10-12 weeks old) were divided in 5 groups: 1) TGF-b1 injection in the TA (TGI), 2) vehicle injection (VI), 3) TGI plus daily vardenafil (orally), 4) TGI plus daily tamoxifen (intraperitoneal), 5) TGI plus daily combination of the two drugs. 5 weeks after injection and/or daily treatment the rats were subjected to erectile function measurement (ICP/MAP) by stimulation of the cavernous nerve at different voltages (5-15V). The penis was harvested for subsequent analysis. RT-qPCR was performed for numerous fibrotic markers. Western blots (WB) were used to assess the contents of a-smooth muscle actin (ASMA), collagens, and their ratios. Histochemistry (HC) visualised cellular infiltration, collagen and SMA content in the penis.
RESULTS: ICP/MAP revealed that TGI lead to a 55% decrease in erectile function which was prevented in the treatment groups. Treatment groups showed no significant differences compared to the VI group. RT-qPCR displayed a 10-fold downregulation in expression of ASMA in the TGI group, with upregulation upon drug treatment. Expression of collagens I, III, and V was upregulated in the TGI group, but not in the VI or treated groups. The drug combination exerted a synergistic effect on the downregulation of elastin. WB showed a 50% reduction in ASMA content in the TGI group, but not the treatment groups, with a synergy observed in the combined group. ASMA/Col I ratio was significantly increased in the vardenafil and combined groups, while ASMA/Col III, and Col I/Col III ratios were only significantly improved in the combined group. HC confirmed the results by visualising effects on tissue level.
CONCLUSIONS: An anti-fibrotic effect could be confirmed for vardenafil, tamoxifen, and their combination on a functional, histological and molecular level in an animal model of the acute phase for PD. The drugs synergise for elastin downregulation, ASMA restoration, and improvement of ASMA/Col and Col I/Col III ratios, showing potential for a novel early treatment strategy for PD.
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PD49-06 IMPAIRED PREFRONTAL-AMYGDALA PATHWAY, SELF-REPORTED EMOTION AND ERECTION IN PSYCHOGENIC ERECTILE DYSFUNCTION PATIENTS WITH NORMAL NOCTURNAL ERECTION
Jianhuai Chen*, Yun Chen, Guotao Chen, Yutian Dai, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Neuroimaging studies had demonstrated that the prefrontal cortex (PFC) and amygdala were associated sexual arousal (SA). However, little was known about how the interactions between the prefrontal and cortex amygdala mediated the cognitive regulation of emotion and SA. We sought to determine whether nocturnal erection of psychogenic erectile dysfunction (pED) patients were normal and whether there were changes of topological organization in the prefrontal-amygdala pathway of brain network in pED. In addition, whether there were correlations between network property changes and self-reported emotion and erection.
METHODS: We used RigiScan device to evaluate erectile function of petients and employed diffusion MRI and graph theory to construct brain networks of 21 pED patients and 24 healthy controls. We considered 4 nodal metrics, their asymmetry scores and nocturnal penile tumescence (NPT) parameters, to evaluate the topological properties of brain networks of pED and its relationships with the impaired self-reported emotion and erection.
RESULTS: All the pED patients showed normal nocturnal penile erection, however impaired slef-reported erection and negative emotion. In addition, patients showed lower connectivity degree and strength in the left prefrontal-amygdala pathway. We also found that pED exhibited lower left-greater-than-right asymmetry in the inferior frontal gyrus. Furthermore, patients showed more hub regions and lesser pivotal connections. Moreover, the degree of the left amygdala of pED showed significantly negative correlation with the self-reported erection and positive correlation with the self-reported negative emotion.
CONCLUSIONS: In this report, we used RigiScan device to evaluate erectile function and explored the self-reported emotion-and erection-related differences in the patterns of pED brain networks. We found that nocturnal erection of pED were normal, however, the prefrontal-amygdala pathway involved in the abnormal SA of pED were impaired. We concluded that the abnormal integration within the left prefrontal-amygdala pathway was associated with the impaired erection and negative emotion in pED. Together, these results showed normal nocturnal erection in pED. However, abnormalities of brain network organization in pED, particularly in the left prefrontal-amygdala pathway, were associated with the impaired self-reported erection and negative emotion. It is controversial that 5-alpha reductase inhibitors (5ARI) are related to permanent erectile dysfunction (ED) even after discontinuation. This study is to investigate the effects of dutasteride on the persistent ED after discontinuation of dutasteride in the rat model, depending on the duration of medication.
METHODS: Male rats (n¼76) were assigned to five groups: (i) normal control group; (ii) dutasteride (0.5mg/rat/day) 4-weeks group; (iii) dutasteride 4-weeks plus 2-weeks of resting group; (iv) dutasteride 8-weeks group; (v) a dutasteride 8-weeks plus 2-weeks of resting group. In vivo erectile responses to electrical stimulation were measured, and change of fibrotic factors and smooth muscle/collagen contents in the corpus cavernosum were evaluated in each group using Western blot and Masson's trichrome staining.
RESULTS: The mean weight of rats was 538.8AE12.3 g (normal control), 471.7AE8.5 g (dutasteride for 4 weeks), 504.5AE8.6 g (dutasteride for 4 weeks plus 2 weeks of rest), 560.7AE7.7 g (dutasteride for 8 weeks), and 540.5AE7.3 g (dutasteride for 8 weeks plus 2 weeks of rest), respectively (p > 0.05). In the dutasteride experimental groups, no abnormal behaviour was observed during dutasteride feeding. Dutasteride 4-and 8-weeks feeding groups significantly decreased erectile parameters compared with control group (p < 0.05). Reduced erectile responses were recovered through 2-weeks of drug-free interval in the 4-weeks group, but not in the 8-weeks group. There was no significant change of protein regarding fibrosis-related factors including TGFb1, TGFb2, and p-Smad/Smad in corpus cavernosum after 4-weeks of dutasteride feeding (p > 0.05), but enhanced in the 8-weeks groups (p Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e967
